Erwin Aguilar
Overview
Explore the profile of Erwin Aguilar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conic J, Chetty A, Chen L, Marsh A, Barry S, Pattabhi R, et al.
Aging Med (Milton)
. 2025 Feb;
8(1):e70004.
PMID: 39968005
Objectives: Alzheimer's disease (AD) is a prevalent age-related neurodegenerative disease that affects millions of individuals in the United States. Neuroinflammation is a driver of the neurodegenerative changes that characterize AD,...
2.
Onor I, Ahmed F, Nguyen A, Ezebuenyi M, Obi C, Schafer A, et al.
Am J Med Sci
. 2023 Oct;
367(1):4-13.
PMID: 37832917
The rising prevalence of comorbidities in an increasingly aging population has sparked a reciprocal rise in polypharmacy. Patients with chronic kidney disease (CKD) have a greater burden of polypharmacy due...
3.
Torres H, Naljayan M, Frontini M, Aguilar E, Barry S, Reisin E
Am J Med Sci
. 2020 Aug;
361(1):30-35.
PMID: 32732078
Background: The low prevalence of peritoneal dialysis (PD) (9%) vs. hemodialysis (HD) (88.2%) is partly due to patient dropout from therapy. Methods: This retrospective study identified patients who withdrew from...
4.
Jalal D, McFadden M, Dwyer J, Umanath K, Aguilar E, Yagil Y, et al.
Hemodial Int
. 2016 Sep;
21(2):243-249.
PMID: 27615161
Introduction: Oral phosphate binders are the main stay of treatment of hyperphosphatemia. Adherence rates to ferric citrate, a recently approved phosphate binder, are unknown. Methods: We conducted a post-hoc analysis...
5.
Liao J, Soltani Z, Ebenezer P, Isidro-Carrion A, Zhang R, Asghar A, et al.
Nephron Exp Nephrol
. 2009 Nov;
114(2):e61-8.
PMID: 19887847
Metabolic syndrome increases the risk of developing diabetes as well as cardiovascular and kidney diseases. This research studied the effects of tesaglitazar, a dual-acting peroxisome proliferator-activated receptor (PPAR)alpha/gamma agonist, on...